Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Aditya Bardia(UCLA Health), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Erika Hamilton(Sarah Cannon), Senthil Damodaran(The University of Texas MD Anderson Cancer Center), Junji Tsurutani(SHOWA Medical University), Yui Kawasaki(Daiichi Sankyo (United States)), Kyriakos P. Papadopoulos(Texas Oncology), Toru Mukohara(Juntendo University), Ian E. Krop(Yale Cancer Center), Alexander I. Spira(Virginia Cancer Specialists), Toshio Shimizu(Wakayama Medical University), Anthony W. Tolcher(South Texas Accelerated Research Therapeutics), Takahiro Kogawa(The Cancer Institute Hospital), Aaron Lisberg(APLA Health), Dejan Juric(Massachusetts General Hospital), Hong Zebger‐Gong(Daiichi Sankyo (Germany)), Tadakatsu Nakamura(Daiichi-Sankyo (Japan)), Jonathan Greenberg(Daiichi Sankyo (Germany)), Fumiaki Kobayashi(Daiichi-Sankyo (Japan)), Rie Wong(Daiichi-Sankyo (Japan))
Cited by 158
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
|Cell|2014|2.5k
Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition
|Science|2013|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k